EXCLUSIVE: Capricor Therapeutics Tells Benzinga Co. Signs Binding Term Sheet With Nippon Shinyaku For European Expansion And Commercialization Of Deramiocel For The Treatment Of Duchenne Muscular Dystrophy
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics has signed a binding term sheet with Nippon Shinyaku to expand and commercialize Deramiocel in Europe for treating Duchenne Muscular Dystrophy.
September 17, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Capricor Therapeutics has entered into a partnership with Nippon Shinyaku to expand and commercialize its product Deramiocel in Europe, targeting Duchenne Muscular Dystrophy.
The partnership with Nippon Shinyaku is a significant step for Capricor Therapeutics as it opens up the European market for Deramiocel, potentially increasing revenue and market presence. This is likely to have a positive short-term impact on CAPR's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100